Full-Time

Associate Principal Scientist

Clinical Research

Deadline 9/22/26
Merck

Merck

10,001+ employees

Pharmaceutical company developing medicines and vaccines

Compensation Overview

$142.4k - $224.1k/yr

+ Annual bonus + Long-term incentive

No H1B Sponsorship

Boston, MA, USA + 3 more

More locations: South San Francisco, CA, USA | West Point, PA, USA | Rahway, NJ, USA

Hybrid

Hybrid work arrangement; travel requirements are 10%. No relocation support is provided.

Bachelor's, Master's, PhD

Category
Biology & Biotech (1)
Required Skills
Risk Management

Get referred to Merck

See people who can refer or advise you

Requirements
  • A degree in Life Sciences with one of the following experience pathways: a Bachelor's degree and at least 11 years of related experience, a Master's degree and at least 8 years of related experience, or a PhD or doctorate degree and at least 3 years of related experience.
  • At least 6 years of Phase 1 clinical trial experience or at least 8 years of Phase 2–3 clinical trial experience.
  • Experience developing, implementing, and managing vaccine clinical programs and trials to ensure efficient, timely execution against milestones.
  • Ability to think creatively, explore novel ways of working, and navigate ambiguity to drive results.
  • Ability to solve complex problems and use independent judgment relating to regulations, guidelines, and investigator interactions.
  • Ability to quickly develop working scientific knowledge of different therapeutic areas.
  • Demonstrated excellence in complex project management and effectively managing multiple projects and priorities across functional boundaries and cultural differences.
  • Demonstrated excellence in scientific, medical and safety writing, and reporting.
  • Ability to work independently across functional areas, make data-driven decisions, identify and appropriately escalate potential issues, and plan mitigations within a study, program, or initiative.
  • Proven ability to partner effectively with external teams to achieve results.
  • Effective written and oral communication, problem-solving, and analytical skills.
  • Working knowledge of Good Clinical Practice, International Council for Harmonisation guidelines, and regulatory requirements.
  • Ability to mentor junior staff.
  • Demonstrated leadership or participation in a cross-functional initiative addressing a business gap or process improvement.
  • Must act with courage and candor.
Responsibilities
  • Provide operational and scientific leadership and therapeutic expertise for the design, planning, and execution of early-phase clinical trials and programs in collaboration with the Clinical Director and cross-functional teams.
  • Oversee, provide strategic direction for, and execute vaccine trials and programs.
  • Manage cross-functional team performance to achieve trial objectives and address issues as they arise.
  • Ensure execution excellence and compliance with Good Clinical Practice, International Council for Harmonisation, and regulatory requirements.
  • Ensure appropriate clinical safety assessment and risk management of compounds.
  • Provide real-time oversight of ongoing trials to identify and mitigate participant, study design, data, and study conduct issues.
  • Review and interpret clinical trial data and participate in on-site study monitoring, including site training and supervision of complex, novel endpoint and biomarker collection processes.
  • Represent Early Stage Development on early development and product development teams.
  • Lead the development of departmental job aids and standard operating procedures.
  • Participate in or lead cross-functional teams developing global clinical development procedures.
  • Identify and communicate best practices across the organization.
  • Promote departmental adoption of new procedures and build junior team members’ capabilities through coaching, mentoring, and development opportunities.
  • Represent the company at professional events and present clinical initiatives, projects, and clinical trial results.
  • Author clinical protocols, investigator brochures, clinical study reports, health authority update reports, responses to regulatory agencies and audits or inspections, and other clinical and regulatory documents.
  • Author and coordinate the development of WMA/CTD subsections.
  • Assist Clinical Directors with scientific leadership and investigator initiatives, including publications, meeting presentations, and due diligence activities.
  • Ensure documents are completed in accordance with applicable standards.
  • Develop study operational documents with team input, including site monitoring plans, study operations and laboratory manuals, risk language, and informed consents.
  • Lead and direct teams through key study planning, development, and execution activities, including program overviews, issue escalation and mitigation, senior management presentations, cross-functional governance meetings, and advisory meeting preparation.
  • Manage trial and program projects, including team meetings and collaborative workspace and document management.
  • Provide risk assessments and contingency planning under accelerated timelines.
Desired Qualifications
  • An advanced degree.
  • Experience with global Phase 1 trials, safety reporting, and regulatory NDA/WMA submission.

Merck is a global healthcare company that develops medicines, vaccines, and animal health products. It advances long-term health by conducting research and development to create new treatments for diseases such as cardiovascular disease, diabetes, and cancer, then brings these medicines to patients, healthcare professionals, and institutions worldwide. The company’s products work by undergoing scientific discovery, clinical testing, and regulatory approval before being manufactured and sold or distributed through patient assistance programs. What sets Merck apart is its large, diversified portfolio across human medicines, vaccines, and animal health, along with a strong emphasis on R&D, global reach, and support services like Merck Connect and Merck Manuals that provide professional resources. Merck’s goal is to tackle major health threats by applying science to discover and deliver therapies that improve patient outcomes and public health across the globe.

Company Size

10,001+

Company Stage

IPO

Headquarters

Kenilworth, Illinois

Founded

1891

Get referred to Merck

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2026 melanoma data validated Merck's next-generation cancer franchise beyond Keytruda.
  • July 2026 Lipfendra approval opens a new cardiovascular growth market before Keytruda erosion.
  • February 2026 oncology reorganization concentrates resources ahead of patent expiry and late-stage launches.

What critics are saying

  • Keytruda loses U.S. compound patent protection in December 2028, pressuring oncology revenue.
  • Summit and Akeso's ivonescimab beat Keytruda in China lung cancer data in 2026.
  • Merck's 2025 $3 billion cost-cutting plan includes 6,000 layoffs, signaling margin strain.

What makes Merck unique

  • Keytruda remains Merck's oncology engine; July 2026 approvals expanded perioperative bladder and kidney use.
  • August 2026 Moderna partnership produced first positive Phase 3 individualized mRNA cancer vaccine results.
  • Lipfendra's July 2026 FDA approval created Merck's first oral PCSK9 inhibitor.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

-20%

1 year growth

-20%

2 year growth

-20%
Yahoo Finance
Sep 8th, 2026
Merck cuts 54 jobs in New Jersey as part of $3B cost-reduction plan

Merck & Co. will lay off 54 workers at its Rahway, New Jersey facility in two phases on 11 December 2026 and 4 January 2027, according to a September filing with the state Department of Labor. The cuts are part of a company-wide initiative announced in 2025 to reduce costs by $3 billion by 2027. The pharmaceutical company said savings from the cost-cutting measures would support new products. This follows a previous notice filed in June covering 88 employees, with layoffs scheduled for 4 September. The company has not disclosed the total number of job cuts planned under the initiative.

World Today News
Sep 8th, 2026
Tempus AI raises $600M to scale AI-enhanced liquid biopsy platform for cancer recurrence detection

Tempus AI has raised $600 million in Series C funding to scale its machine learning platform for cancer recurrence detection through liquid biopsies. The investment was led by SoftBank Vision Fund 2, with participation from Roche and Merck. Phase II trial data showed the AI-enhanced liquid biopsy analysis reduced false-negative results by 37% compared to conventional methods. The platform uses deep learning algorithms trained on over 12,000 genomic profiles to identify circulating tumour DNA fragments shed by residual cancer cells. A 2025 Nature Medicine study reported the system achieved 92% specificity in detecting minimal residual disease across breast, lung, and colorectal cancers. According to SEC filings, 45% of funds will support FDA pre-market approval trials, whilst 30% will fund global expansion into EU and APAC markets.

Latest Nigerian News
Sep 5th, 2026
Merck, Cond Nast and Cargill all recently appointed female cfos.

Merck, Cond Nast and Cargill all recently appointed female cfos. Published by Forbes on Fri, 02 Apr 2021 March was a great month for women in finance. Last week, pharmaceutical giant Merck tapped Caroline Litchfield as its new CFO, while media company Cond Nast named Jackie Marks to lead its finance function. Earlier in the month, food corporation Cargill announced Jamie Miller as finance chief.

BioSpace
Sep 3rd, 2026
Summit, Akeso's ivonescimab bests Merck's Keytruda in China trial - again.

Summit, Akeso's ivonescimab bests Merck's Keytruda in China trial - again. September 3, 2026 | New Phase 3 data show that Summit Therapeutics and Akeso's PD-1/VEGF therapy improved overall survival in patients with a type of lung cancer as compared to Merck's Keytruda but the results will need to be replicated in non-Chinese patients. Summit Therapeutics and Akeso's upcoming PD-1/VEGF bispecific antibody has officially bested Merck's mega-blockbuster Keytruda on both overall survival and progression free survival in a type of non-small cell lung cancer. The latest results for the partners could establish a new paradigm in NSCLC treatment where ivonescimab becomes the regimen of choice among oncologists, analysts said. But the new data from the Phase 3 HARMONi-2 trial comes from Chinese clinical trials. Summit still has to verify the results in Western patients to get the FDA on board for a clean regulatory review. Akeso on Thursday announced interim results from the Phase 3 HARMONi-2 trial, which compared ivonescimab against Keytruda in patients with first-line NSCLC with tumors that express PD-L1. The drug is already approved in China for this type of cancer, as well as two others, but has yet to be cleared in the U.S. for any indication. Ivonescimab met the key secondary goal of improving overall survival (OS). The companies previously announced the achievement of the main progression-free survival (PFS) endpoint in May 2024, earning the antibody the nickname Keytruda killer. The therapy achieved PFS of 11.14 months as compared to Keytruda's 5.82 months. Summit Therapeutics planned an early interim progression-free survival readout for HARMONi-3 in the hope of enabling earlier regulatory engagement - but the early analysis delivered disappointment for the company and shareholders. May 4, 2026 "Akeso's HARMONi-2 study has now demonstrated both PFS and OS superiority versus Keytruda in China, raising the possibility that future NSCLC regimens may increasingly be judged against ivonescimab rather than Keytruda," Jefferies wrote in a Thursday morning note. "While investors can reasonably debate whether China data will fully translate globally," the analysts continued, "this latest OS readout strengthens the case for ivonescimab as a potential next-generation immunotherapy backbone in NSCLC." Summit's shares rose over 7% to $15.65 in early morning trading Thursday. Akeso did not reveal detailed data on the OS endpoint but promised to do so at a future medical meeting and in a peer-reviewed journal. In the meantime, Summit is working on confirming these achievements in trials conducted elsewhere. A key test will be the outcome of the global Phase 3 HARMONi-3 trial, which is testing ivonescimab with chemotherapy against Keytruda in patients with first-line metastatic NSCLC. After the drug was approved for this indication in China, the regulator there released additional data on the label that suggested a degradation of the PFS benefit. Analysts raised concerns that the HARMONi-3 trial may not show a sufficient benefit to warrant an accelerated approval from the FDA. Summit is expected to reveal data from HARMONi-3 sometime this half. In May, an early interim analysis of PFS from HARMONI-3 failed to reach statistical significance, postponing Summit's plans for a regulatory filing in this indication. Summit is, however, currently awaiting a November FDA decision for the therapy in NSCLC with mutations in the gene for epidermal growth factor receptor (EGFR). Analysts, investors and partner Summit Therapeutics had all been keenly awaiting the overall survival update, after previous data from Akeso's HARMONi-6 trial left them wanting. May 31, 2026

DIGITIMES
Sep 3rd, 2026
Electroninks, Merck, Qualipoly build advanced packaging ecosystem.

Electroninks, Merck, Qualipoly build advanced packaging ecosystem. Sep 4, 2026, 07:53 0 Credit: DIGITIMES Electroninks, a global provider of metal-composite conductive inks and advanced semiconductor packaging materials, has formed a strategic partnership with Merck and Taiwan-based Qualipoly Chemical to offer advanced packaging customers a more complete, faster,... Picks for you